KR910011787A - 항혈전성 화합물 - Google Patents

항혈전성 화합물 Download PDF

Info

Publication number
KR910011787A
KR910011787A KR1019900021184A KR900021184A KR910011787A KR 910011787 A KR910011787 A KR 910011787A KR 1019900021184 A KR1019900021184 A KR 1019900021184A KR 900021184 A KR900021184 A KR 900021184A KR 910011787 A KR910011787 A KR 910011787A
Authority
KR
South Korea
Prior art keywords
compound
patient
treating
administering
amount
Prior art date
Application number
KR1019900021184A
Other languages
English (en)
Other versions
KR0184641B1 (ko
Inventor
안토니 카 알버트
사이러스 데이지 리챠드
에드나 코에너 존
리 텅
피터 밀러 프란시스
로버트 니두작 타데우스
윌리암 듀들레이 마크
Original Assignee
게리 디. 스트리트
메렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 메렐 다우 파마슈티칼스 인크. filed Critical 게리 디. 스트리트
Publication of KR910011787A publication Critical patent/KR910011787A/ko
Application granted granted Critical
Publication of KR0184641B1 publication Critical patent/KR0184641B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

향혈전성 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 다음 일반식(I)의 화합물 및 이들의 제약상 허용되는 산부가염.
  2. 제1항에 있어서, X가 CO인 화합물.
  3. 제1항에 있어서, X가 SO2인 화합물.
  4. 혈전중 환자에게 항혈전량의 제1항의 화합물을 투여하는 것으로 되는 혈전증의 치료 방법.
  5. 변형 앙기나증 환자에게 항앙기나량의 제1항의 화합물을 투여하는 것으로 되는 변형 앙기나의 치료 방법.
  6. 식욕불량증 환자에게 항식욕불량량의 제1항의 화합물을 투여하는 것으로 되는 신경 식욕 불량증의 치료 방법.
  7. 레너드 현상(Raynaud′s phenomemon)의 치료를 요하는 환자에게 제1항의 화합물을 환자의 증후를 없애거나 완화시키기에 충분한 양으로 투여하는 것으로 되는 레너드 현상 치료법.
  8. 관상 혈관경련증 환자에게 항혈관경련량의 제1항의 화합물을 투여하는 것으로 되는 관상 혈관경련증의 치료 방법.
  9. 신경근육통 환자에게 항신경근육통량의 제1항의 화합물을 투여하는 것으로 되는 신경근육통의 치료 방법.
  10. 추체외로 부작용(EPS)치료를 요하는 환자에게 항 EPS양의 제1항의 화합물을 투여하는 것으로 되는 신경이완 치료에 관련된 추체외로의 부작용의 치료 방법.
  11. 불안증 환자에게 불안해소량의 제1항의 화합물을 투여하는 것으로 되는 불안을 없애거나 완화시키는 방법.
  12. 부정맥증 환자에게 항부정맥량의 제1항의 화합물을 투여하는 것으로 되는 부정맥증의 치료 방법.
  13. 정신질환증 환자에게 유효량의 제1항의 화합물을 투여하는 것으로 되는 정신질환의 치료 방법.
  14. 제1항의 화합물과 불활성 담체가 혼합되어 이루어진 조성물.
  15. 제14항에 있어서, 상기 불활성 담체가 제약 담체인 조성물.
  16. 제15항에 있어서, 트롬복산 합성효소 억제제를 함유한 조성물.
  17. Y가 할로겐 원자인 다음 일반식(Ⅱ)로 표시되는 2-할로-4′-플루오로-아세토페논와, 및 X가 CO 또는 SO2인 다음 일반식(Ⅲ)으로 표시되는 -아세트아미도- 또는 메탄술폰아미도 유도체 간에 N-알킬화를 행하는 것으로 이루어진 다음 일반식(I)의 화합물의 제조 방법.
    식 중, X는 CO 또는 SO2이다.
  18. 제1항에 따른 화합물의 의약으로서 용도.
  19. 제1항에 따른 화합물의 항혈전성 의약으로서의 용도.
  20. 제1항에 따른 화합물의 항정신성 의약으로서의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900021184A 1989-12-21 1990-12-20 항혈전성 화합물 KR0184641B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45449789A 1989-12-21 1989-12-21
US454497 1989-12-21
US60465190A 1990-11-01 1990-11-01
US454,497 1990-11-01
US604651 1990-11-01
US604,651 1990-11-01

Publications (2)

Publication Number Publication Date
KR910011787A true KR910011787A (ko) 1991-08-07
KR0184641B1 KR0184641B1 (ko) 1999-05-01

Family

ID=27037488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900021184A KR0184641B1 (ko) 1989-12-21 1990-12-20 항혈전성 화합물

Country Status (20)

Country Link
EP (1) EP0437790B1 (ko)
JP (1) JP2934323B2 (ko)
KR (1) KR0184641B1 (ko)
CN (1) CN1025853C (ko)
AR (1) AR247200A1 (ko)
AT (1) ATE133163T1 (ko)
AU (1) AU635098B2 (ko)
CA (1) CA2032797C (ko)
DE (1) DE69024933T2 (ko)
DK (1) DK0437790T3 (ko)
ES (1) ES2084642T3 (ko)
FI (1) FI96946C (ko)
GR (1) GR3018895T3 (ko)
HU (1) HU210590B (ko)
IE (1) IE71039B1 (ko)
IL (1) IL96731A (ko)
NO (1) NO176565C (ko)
NZ (1) NZ236501A (ko)
PT (1) PT96291B (ko)
TW (1) TW199145B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292752A (en) * 1989-12-21 1994-03-08 Merrell Dow Pharmaceuticals Inc. Antithrombotic compounds
US5478846A (en) * 1990-06-07 1995-12-26 Merrell Dow Pharmaceuticals Inc. 1-piperidinyl alkanoylanyl sulfonamides for treatment of cardiac arrhythmia
AU650031B2 (en) * 1990-06-07 1994-06-09 Aventisub Ii Inc. 1-Piperidinyl alkanoylarylsulfonamide derivatives
EP0661266A1 (en) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355037A (en) * 1981-11-12 1982-10-19 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidyl)-1,2-benzisoxales
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
PH23283A (en) * 1986-02-26 1989-06-30 Eisai Co Ltd Piperidine derivative, pharmaceutical composition containing the same and method of use thereof
DE3750580T2 (de) * 1987-01-12 1995-05-24 Dominic A Ricchio Vorrichtung und verfahren zur verbesserten wassermassage.
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
CA2032797A1 (en) 1991-06-22
NO176565C (no) 1995-04-26
NO905511L (no) 1991-06-24
EP0437790A2 (en) 1991-07-24
IE904632A1 (en) 1991-07-17
DE69024933T2 (de) 1996-05-30
IL96731A (en) 1995-06-29
EP0437790A3 (en) 1992-04-08
FI96946B (fi) 1996-06-14
HU908370D0 (en) 1991-07-29
DE69024933D1 (de) 1996-02-29
CN1052664A (zh) 1991-07-03
EP0437790B1 (en) 1996-01-17
CN1025853C (zh) 1994-09-07
CA2032797C (en) 2002-03-19
NO905511D0 (no) 1990-12-20
AU6818190A (en) 1991-06-27
IE71039B1 (en) 1997-01-15
AR247200A1 (es) 1994-11-30
GR3018895T3 (en) 1996-05-31
FI96946C (fi) 1996-09-25
KR0184641B1 (ko) 1999-05-01
TW199145B (ko) 1993-02-01
FI906246A0 (fi) 1990-12-18
FI906246A (fi) 1991-06-22
PT96291A (pt) 1991-09-30
ATE133163T1 (de) 1996-02-15
JPH04145068A (ja) 1992-05-19
HU210590B (en) 1995-05-29
JP2934323B2 (ja) 1999-08-16
AU635098B2 (en) 1993-03-11
ES2084642T3 (es) 1996-05-16
NZ236501A (en) 1992-12-23
PT96291B (pt) 1998-06-30
NO176565B (no) 1995-01-16
DK0437790T3 (da) 1996-02-12

Similar Documents

Publication Publication Date Title
KR930700103A (ko) (+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올
MX9203543A (es) Medicamento.
KR880002834A (ko) α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도
KR880007514A (ko) 키놀린 화합물
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
ATE138663T1 (de) Oxothiolane und derivate, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als arzneimittel
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
FI861410A0 (fi) Foerfarande foer framstaellning av terapeutiskt aktiva aminopropanolderivat.
KR910011787A (ko) 항혈전성 화합물
KR910009259A (ko) 천식 또는 특정 피부 질환의 치료를 위한 피리미돈 유도체 및 동족체
NO158677C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoksazol-derivater.
KR890004705A (ko) 항바이러스성 제제
GB8924528D0 (en) Heterocyclic pharmaceutical compounds,preparation and use
EP0270046A3 (en) Pharmaceutical composition for treatment of cataract
KR880004810A (ko) 소화성 궤양 치료제
GB2122197B (en) Antiviral guanine derivatives
AU560542B2 (en) Pyridazine derivatives which have c.n.s. activity
FI892685A0 (fi) Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi
ZA885358B (en) Uricosuric composition
KR890002222A (ko) 치매 치료제
GB2015500A (en) Disubstituted Piperazines, Process for Their Preparation and Pharmaceutical Compositions Containing Them
ZA851429B (en) Quinate salts of the antimalarial compound mefloquine
TH5989A (th) นิวคลีโอไซด์ที่ใช้รักษาโรค

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20021211

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee